[New cell target treatments: indications, results and tolerance].
Bellmunt
Joaquim
J
Servicio de Oncología Médica (GU y GI), Hospital del Mar, Barcelona, España. jbellmunt@imas.imim.es
Gelabert-Mas
Antoni
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor